Objective: To assess whether noninvasive proton magnetic resonance spectroscopy ( 1 H-MRS) tissue metabolite measurements at baseline can predict an increase in the rate of b-amyloid (Ab) accumulation on serial PET in clinically normal (CN) older adults.
Twenty to forty percent of clinically normal (CN) older adults have significant b-amyloid (Ab) load on cross-sectional PET. [1] [2] [3] An increased rate of Ab accumulation may put them at a higher risk for cognitive decline 4 and mild cognitive impairment (MCI). 5 Cost-effective and noninvasive biomarkers that can predict a further increase in Ab accumulation over time are necessary for better identification of at-risk individuals who may benefit from preventive and diseasemodifying strategies.
In CN older adults, elevated myo-inositol (mI), a marker of glial activation, has been associated with a higher Ab load on PET, 6, 7 lower CSF Ab 1-42 , 7 and a higher Ab density in an autopsy-confirmed cohort. 8 Moreover, an elevated mI has been found in APOE e4 carriers with no evidence of Ab deposition on PET. 7 Although the mechanistic relationship between APOE e4 and elevated mI is unclear, it has been suggested that APOE e4 enhances glial activation and modulates the relationship between Ab and glial activation. [9] [10] [11] However, the APOE e4 effect on magnetic resonance spectroscopy (MRS) metabolite levels among CN elderly has been equivocal. 7, 9, 12 Further, all of the studies examining MRS, Ab-related pathology, and APOE e4 were cross-sectional.
Our objective was to investigate the association of MRS metabolite ratios from a posterior cingulate (PC) gyrus voxel at baseline with the change in Ab accumulation over time on serial amyloid PET in CN older adults drawn from a population-based sample. A secondary objective was to assess whether APOE e4 modifies the relationship between MRS metabolites and the rate of Ab accumulation.
METHODS Participants. Consecutive participants aged $60 years were drawn from the ongoing population-based, longitudinal Mayo Clinic Study of Aging, 13, 14 between January 2006 and May 2016. To be included in this imaging study, participants were required to be CN at baseline when MRS and amyloid PET were performed and have at least one follow-up amyloid PET. The diagnostic process and criteria for being clinically normal are described in appendix e-1 at Neurology.org. A total of 594 participants meeting inclusion criteria and passing image quality control were included in the analyses. The final cohort flowchart is provided as figure e-1.
Blood was collected to determine the APOE e4 noncarrier or carrier status.
Change in Ab accumulation over time was assessed using all available follow-up amyloid PET examinations on an individual. Consecutive participants had 1 (n 5 416; 70%), 2 (n 5 144; 24.6%), 3 (n 5 29; 4.8%), or 4 (n 5 5; 0.6%) follow-up PET scans performed approximately every 15 months.
Standard protocol approvals, registrations, and participant consents. The Mayo Clinic and Olmsted Medical Center institutional review boards approved the study. Every participant provided written informed consent.
1 H-MRS and MRI studies. Baseline MRS and MRI were performed at 3T using an 8-channel phase array coil (GE Healthcare, Waukesha, WI). A 3D high-resolution T1-weighted magnetizationprepared rapid acquisition gradient echo (MPRAGE) scan was acquired for anatomic segmentation and region labeling of PET and localization of 1 H-MRS voxel. A point-resolved spectroscopic sequence was acquired with repetition time/echo time 2,000/30 ms with a single voxel of 2 3 2 3 2 cm 3 placed in the midsagittal MPRAGE image including right and left PC gyri and inferior precunei. Although the transverse relaxation time of N-acetylaspartate (NAA) and choline (Cho) is longer than mI, a single short echo time of 30 ms allowed measurements of all 3 metabolites in participants within the Alzheimer disease (AD) continuum. 15 Metabolites were quantified using the automated proton brain examination/single-voxel package, and their intensities were scaled by creatine (Cr), a standard reference. Individual voxel placement and magnetic resonance spectra were visually evaluated by a trained image analyst for quality control. A trained image analyst reviewed the location of the MRS voxel and evaluated water suppression, baseline distortions, or lipid contamination. Voxels that did not include the PC location according to the predetermined anatomic landmarks and spectra with poor water suppression, lipid contamination, or baseline distortions failed quality control and were excluded. Although the spectral fit was not measured quantitatively, the quantification of metabolite ratios failed if the spectral fit was poor.
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C-Pittsburgh compound B (PiB)-PET/CT images were acquired using a GE scanner (GE Healthcare). Participants were injected with the PiB tracer (average activity 625 MBq; range 385-723) and a low-dose CT scan was acquired for attenuation correction. Forty to sixty minutes postinjection, a 20-minute dynamic PET scan consisting of four 5-minute frames was acquired. These 4 frames were averaged to create a single statistical image.
Cortical Ab retention for each PiB image was calculated as a global cortical standardized uptake value ratio (SUVR). 16 For measuring change over time in PiB uptake, we used a previously published SUVR measurement technique, which was demonstrated to improve reliability and plausibility for serial measurements compared to traditional cross-sectional approaches. 17 This technique uses a reference region of eroded supratentorial white matter (WM) segmented using MRI, combined with the whole cerebellum and pons. In brief, each PiB scan is rigidly registered to its corresponding T1-weighted MRI. Each MRI is segmented using SPM12 18 with an in-house population-specific template and several population-specific measure alterations previously described. 19 These segmentations are used for locating supratentorial WM for the reference region.
The target region and the cerebellar/pons regions included as part of the reference region were each localized using a corresponding in-house atlas 19 that was nonlinearly registered to each corresponding MRI using the advanced normalization tools symmetric normalization algorithm, 20 resampled using nearestneighbor interpolation, and refined using the tissue segmentations described above. Automated registration and segmentation steps were each visually confirmed for acceptable quality. SUVRs were then calculated from PiB scans as the mean of all voxels in the target region normalized by the mean of all voxels in the reference region.
Statistical analysis. We used mixed-effects models to model repeated PiB SUVR values as a function of baseline MRS metabolite ratios for all participants. We incorporated random slopes and intercepts for each participant (estimating the correlation between the slopes and intercepts). The primary predictor of interest involved an interaction of baseline MRS ratio with time, because we were interested in longitudinal change in Ab accumulation. Models included the nested time and MRS ratio at baseline as is proper for an evaluation of interaction with time. A significant interaction of MRS ratio at baseline with time would indicate that the increase in the rate of Ab accumulation on serial PET depends upon the value of the MRS ratio at baseline. A significant association between baseline MRS ratio and Ab accumulation in the model would indicate that the MRS ratio was associated with consistently higher Ab accumulation across all serial PET measurements in a given participant but not with an increased rate of accumulation. The models also accounted for effects of baseline age, sex, and APOE e4 status. We computed the 3-way interactions of baseline MRS ratios and APOE e4 status with time to assess whether APOE e4 modifies the relationship between baseline metabolite MRS ratios and change over time in Ab accumulation on serial PET.
Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and R statistical software version 3.1.1 (R-project.org) with 2-sided significance set at a 0.05 type I error rate. Because we were interested in the association of individual metabolite ratios with serial PiB measurements, and at this stage did not want to inflate type II error by declaring true associations null, we did not adjust for multiple comparisons. 21, 22 RESULTS Participants' characteristics at baseline are listed in table 1. Although a higher mI/Cr at baseline was only borderline associated with a higher Ab load across all serial PET of a given participant (p 5 0.06), it is more important that it was significantly associated with a greater increase in rate of Ab accumulation (p 5 0.011), adjusting for baseline age, sex, APOE e4, and the interaction between APOE e4 and age (table 2) . Similarly, a lower baseline NAA/mI was associated with consistently higher Ab load across all serial PETs of a given participant (p 5 0.007), but moreover, it was associated with an increased rate of Ab accumulation (p 5 0.006), adjusting for the same covariates (table 2). Figure 1 illustrates the estimated increase in rate of Ab accumulation by baseline MRS ratios and by APOE e4 with specific estimated values shift according to age, sex, and APOE e4. Figure 2 shows the 3 individuals from the current cohort, their magnetic resonance spectra at baseline, and associated Ab load at baseline and at follow-up.
Mixed-effect models for the remaining metabolite ratios showed that a lower baseline NAA/Cr was associated with consistently higher Ab load across all serial PET examinations in a given participant (p 5 0.02; table e-1). However, NAA/Cr was not associated with an increased rate of Ab accumulation (p 5 0.18; figure e-2). Cho/Cr was associated neither with Ab load across serial PET (p 5 0.28) nor with rate of Ab accumulation (p 5 0.47; table e-1).
APOE e4 was associated with consistently higher Ab load across all serial PiB SUVR measurements (p , 0.001). Furthermore, the interaction of APOE e4 with time (p , 0.001) was associated with an increased rate of Ab accumulation, taking into account baseline age, sex, and time with baseline age interaction (table 3, model 1; figure 1 ). However, an accelerated rate of Ab accumulation in APOE e4 carriers compared to noncarriers may be because APOE e4 carriers have higher baseline Ab load. 16 Nevertheless, when we compared rates of Ab accumulation between a subset of our APOE e4 carriers (n 5 149) and noncarriers matched on age, sex, and baseline Ab load to a subset of our noncarriers (n 5 149), the interaction between APOE e4 and time remained significant (p 5 0.001; table 3, model 2) using mixed-effect model with a random block design to account for matching. Therefore, APOE e4 carriers accumulated Ab at an accelerated rate compared to APOE e4 noncarriers even when they had a similar baseline Ab load (figure 1).
Finally, we assessed whether APOE e4 status modified the relationship between the baseline metabolites and increased rate of Ab accumulation using a 3-way interaction of baseline metabolites, APOE e4, and time among all. None of these interactions was significant, including for mI/Cr 3 APOE e4 3 time (p 5 0.35) and for NAA/mI 3 APOE e4 3 time (p 5 0.90). Therefore, longitudinally, APOE e4 status did not modify the relationship between MRS metabolites and rate of Ab accumulation on serial PET. DISCUSSION In this large cohort of CN older adults, mean age of 74, drawn from a populationbased sample, we demonstrated that noninvasive and inexpensive baseline MRS metabolite levels are associated with an increased rate of Ab accumulation on serial PET. Lower NAA/mI and higher mI/Cr at baseline were associated with an increased rate of Ab accumulation taking into account age at baseline, sex, and APOE e4 status. APOE e4 carriers accumulated Ab faster than noncarriers. APOE e4 status did not alter the relationship between baseline metabolite levels and rate of Ab accumulation and both MRS metabolites and APOE e4 likely are independently associated with an increased Ab accumulation over time.
An elevated mI/Cr has been consistently associated with biomarkers of elevated Ab in CN adults cross-sectionally. 7, 8, 23, 6 Moreover, in the transgenic 40 murine AD model, a passive immunization with antiAb antibodies lessened the mI/Cr in the treatment arm compared to placebo. 24 In the current longitudinal cohort, we demonstrated findings that suggest an elevated mI/Cr as a predictor of an accelerated Ab accumulation over time on serial PET.
NAA/Cr ratio, a marker of neuronal viability and synaptic integrity, is reduced in participants with MCI 25 and AD, 15, 26, 27 but not in CN older adults, suggesting that a decline in NAA/Cr is preceded by an increased mI/Cr during the course of AD. In line with this, an autopsy-confirmed study 8 demonstrated an association between a lower NAA/Cr and a higher burden of tau-related pathology and loss of synaptic integrity that is believed to follow the changes in Ab biomarkers during the course of AD. 28 Accordingly, we observed that a lower NAA/Cr was associated with consistently higher Ab load across all serial PET examinations of a given participant but not with an increased rate of Ab accumulation. In addition to mI/Cr, significant association was observed between a lower baseline NAA/mI and an increased rate of Ab accumulation. Lower NAA/mI has predicted progression from CN to MCI in a population-based cohort 29 and only a lower NAA/mI among routinely examined MRS ratios correlated with both greater tau and Ab burden at autopsy. 8 The current study supports the composite NAA/mI ratio as a marker of increased longitudinal Ab accumulation in CN older adults.
Although Cho/Cr has been associated with a higher Ab load on PET 7,29 and a worse cognitive performance in CN older adults, 6,9 we did not observe an association of Cho/Cr and rate of Ab accumulation. No association was found between Cho/Cr and ADrelated pathology in an autopsy-confirmed cohort, 8 and the significance of Cho/Cr during the progression of AD remains unclear.
APOE e4 status did not modify the relationship between baseline MRS metabolites and rate of Ab accumulation on serial PET. Instead, APOE e4 was independently associated with an accelerated Ab accumulation. Whereas the relationship between a higher Ab load in APOE e4 carriers has been well-established cross-sectionally, 3, 30, 31 the effect of APOE e4 status on longitudinal Ab accumulation in CN older adults has not been clarified, likely due to small sample sizes, various PiB uptake measurement approaches, and different interpretation of contributing effects of baseline Ab load, age, sex, and number of available follow-up PET scans. 5, [32] [33] [34] Moreover, APOE e4 effect on longitudinal Ab accumulation may be mediated by baseline Ab load, 16 which is higher in APOE e4 carriers than noncarriers. Higher baseline Ab load is a risk factor for increased Ab accumulation over time. 16 However, our finding of longitudinally accelerated Ab accumulation in APOE e4 carriers with similar baseline Ab load to APOE e4 noncarriers indicates that APOE e4 carriers accumulate Ab faster than noncarriers, regardless of baseline Ab levels.
A cross-sectional study by Voevodskaya et al. 7 demonstrated that already cognitively normal APOE e4 carriers with still normal Ab biomarker levels had elevated mI/Cr. It was suggested that mI/Cr may be an early biomarker of Ab accumulation. 35 Our findings support this hypothesis by showing that an elevated mI/Cr ratio in older adults is associated with an increased rate of Ab accumulation. In addition, we showed that the relationship between MRS metabolite alterations and rates of Ab accumulation is independent of APOE e4 status. Taken together, these findings suggest that cross-sectional MRS metabolite alterations may occur in APOE e4 carriers because of their risk of increased Ab accumulation over time.
Higher baseline Ab load increases the risk of cognitive decline over time in CN older adults. 34, 36 However, a recent cut point for Ab positivity on PET in CN older adults 37 was based on repeated measurements of Ab accumulation. Using repeated measurements, the reliable worsening in Ab accumulation was identified and served as cut point. Moreover, a few studies demonstrated that an increased rate of Ab accumulation on PET is associated with cognitive decline over time in CN 4 and progression to MCI. 5 Therefore identifying those who accumulate Ab faster over time provides additional and valuable information on at-risk individuals beyond crosssectional measurements, which do not provide any information on disease progression. However, so far, the biomarkers that would identify such individuals have been scarce. Identifying those who accumulate Ab faster can have important implications for early diagnosis and selecting at-risk individuals for secondary preventive interventions targeted to reduce Ab accumulation rate. It is possible that interventions might be more effective in those who are still clinically normal but on the way to higher rates of Ab accumulation. Our current findings suggest that both MRS metabolite alterations and APOE e4 status independently are associated with accelerated rates of Ab accumulation.
We did not dichotomize the participants as amyloid-positive or -negative by a cut point, although this popular approach may have practical advantages. Instead, we treated serial PiB SUVR as continuous measures that allowed us to include the CN participants with the full range of PiB SUVR values. Cut point may create a gray zone where subthreshold but important relationships might be obscured. For example, the biological difference The rate of Ab accumulation is compared between a 75-yearold male APOE e4 noncarrier and an APOE e4 carrier of the same age and sex (table 3) . The carrier slope is increasing and diverging from the noncarrier slope with time. However, note an obvious difference in baseline Ab load between the APOE e4 carrier and noncarrier, and because of this Ab accumulation might be faster in the APOE e4 carrier. (D) The difference in rate of Ab accumulation is shown between the APOE e4 carrier matched on age, sex, and baseline Ab load to the noncarrier. The APOE e4 carrier accumulates Ab faster, regardless of baseline Ab load. Note that the baseline Pittsburgh compound B (PiB) standardized uptake value ratio (SUVR) is derived using the serial PiB SUVR measurement approach.
between those participants who are close to the cut point, but arbitrarily fall into opposite groups, or a minor longitudinal change that moves a participant from one group to another by a given cut point might be negligible. On the contrary, a large difference in PiB SUVR among 2 participants who are in the same PiB group and a large change in PiB SUVR in a participant over time without a change in PiB group designation by cut point may be very meaningful. Finally, the cut point for amyloid positivity for longitudinal amyloid measurements remains to be established. Strengths of this study are the large sample of individuals drawn from a single population with serial amyloid PET including a large subset of APOE e4 carriers matched to noncarriers on demographics and baseline Ab load. In this cohort, Ab accumulation over time was measured using a modified reference region that has demonstrated an improved reliability and plausibility for serial measurements compared to traditional cross-sectional approaches. 17 The limitations of our study are similar to those of other studies using participants drawn from a population-based sample, such as the presence of various subthreshold pathologies in CN older adults, which may increase the variability of MRS metabolite measurements and weaken some of the studied relationships. However, the levels of MRS ratios in the current cohort of CN older adults were consistent with previous studies by others and by our group, 9, 29, 38 including an autopsy-confirmed study on MRS correlates of Ab accumulation. 8 Our proportion of CN APOE e4 carriers (29%) was similar to previous reports. 5, 32, 34 However, we cannot exclude the potential for participation or survival bias because more educated and generally healthier participants may be more willing to participate longitudinally in imaging studies, 29 and our findings may not be MRS is a noninvasive and inexpensive technique that can be part of a standard clinical magnetic resonance examination, including in clinical trials. However, for these purposes, the standardization and optimization of multicenter MRS studies are necessary. Moreover, a longitudinal investigation of serial MRS metabolites to estimate progression of Ab in participants within the AD continuum would provide additional information on the temporal ordering between the alterations in MRS metabolites and Ab pathophysiology.
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